Stockreport

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF Prelude Therapeutics, Incorporated Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the firs [Read more]